Kazia Therapeutics Limited (KZIA)

NASDAQ: KZIA · IEX Real-Time Price · USD
-0.102 (-14.57%)
At close: Nov 27, 2023, 3:59 PM
+0.072 (12.04%)
After-hours: Nov 27, 2023, 5:50 PM EST

Company Description

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs.

Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma.

It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor.

The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017.

The company was incorporated in 1994 and is based in Sydney, Australia.

Kazia Therapeutics Limited
Kazia Therapeutics logo
Country Australia
Founded 1994
IPO Date Jan 6, 1999
Industry Biotechnology
Sector Healthcare
CEO Dr. John E. Friend II, M.D.

Contact Details

120 Broadway, 32nd Floor
New York, New York 10271
United States
Phone 212 238-3128
Website kaziatherapeutics.com

Stock Details

Ticker Symbol KZIA
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001055886
CUSIP Number 48669G105
ISIN Number US48669G1058
SIC Code 8880

Key Executives

Name Position
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( Chief Executive Officer, MD and Executive Director
Karen R. Krumeich Chief Financial Officer
Dr. John E. Friend II, M.D. Chief Medical Officer
Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD Company Secretary

Latest SEC Filings

Date Type Title
Nov 21, 2017 424B3 Prospectus
Nov 17, 2017 424B3 Prospectus
Jul 11, 2017 424B3 Prospectus
Jun 6, 2016 F-6 POS Post-effective amendments for immediately effective filing